|
Sarcoma
|
1.000 |
CausalMutation
|
group |
CGI |
|
|
|
|
Sarcoma
|
1.000 |
Biomarker
|
group |
HPO |
|
|
|
|
Sarcoma
|
1.000 |
CausalMutation
|
group |
CLINVAR |
|
|
|
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Two of the sarcomas with rearranged genes expressed levels of p53 protein that were elevated relative to other tumors.
|
2823272 |
1987 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Abnormalities of the p53 gene were found in several classes of soft tissue sarcoma, including leiomyosarcomas, rhabdomyosarcomas and malignant fibrous histiocytomas.
|
2216456 |
1990 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
In contrast, no alteration of the p53 gene was detected in 50 samples from other types of sarcomas.
|
2253237 |
1990 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
In particular, the discovery of tumor suppressor gene syndromes, such as Rb1 gene and p53 gene defects manifested in "cancer families," were made possible by their association with sarcomas, otherwise rare tumors.
|
1932226 |
1991 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
New germline mutations of the p53 gene are rare among patients with "sporadic" sarcoma but may be common in patients with sarcoma whose background includes either multiple primary cancers or a family history of cancer.
|
1565143 |
1992 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
In contrast to reported findings for other types of cancer, we found that mutations of the p53 gene in sarcomas are quite heterogeneous both in their distribution throughout the gene and in the type of genetic alterations that result.
|
1423262 |
1992 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
The p53 positivity in MFHs and other types of sarcoma indicates that p53 gene alterations may play a part in the neoplastic transformation of these tumours.
|
1333524 |
1992 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
While "cancer families" are rarely identified when screening close relatives of sarcoma patients, the discovery of the currently known tumor suppressor gene syndromes associated with germ line retinoblastoma gene and p53 gene defects were made possible by their association with sarcomas.
|
1511024 |
1992 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
These results demonstrated the dominance of the p53 mutations with null protein expression in bone and soft tissue sarcomas, showing a unique characteristic of these types of tumours compared with other malignancies such as colon carcinomas.
|
8260365 |
1993 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
The p53 and MDM2 genes were analyzed in 24 human soft tissue sarcomas (11 malignant fibrous histiocytomas and 13 liposarcomas).
|
8387391 |
1993 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
The results indicate that the TP53 gene is involved in the tumorigenesis of several sarcoma subtypes in a higher fraction of cases than was previously recognized.
|
8425179 |
1993 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
We report here on the first set of ten such families, eight of which were identified through a proband with sarcoma. p53 exons 5 to 8 have been sequenced following polymerase chain reaction amplification performed on DNA isolated from total blood.
|
8425176 |
1993 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Specific overexpression of P53 in sarcoma derived from Rat-1 cells transformed by cigarette smoking condensate-treated human fetal lung DNA.
|
7722886 |
1994 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
It is concluded that 17p deletions and TP53 mutations are common events in adult soft tissue sarcomas and that due to the trends observed with the cohort of patients analyzed they may become prognostic markers for patients affected with these tumors.
|
8053493 |
1994 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
We suggest that c-myc amplification and TP53 mutations do not seem to coparticipate in the tumorigenesis of sarcomas.
|
8076351 |
1994 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The most common cancers occurring in the 41 families with germline p53 mutations, in common with classic LFS, were bone and soft tissue sarcoma, breast cancer, brain tumors, leukemia, and adrenocortical carcinoma, although less than one-half of the probands with germline p53 mutations came from classic LFS families.
|
8118819 |
1994 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
This study was designed to determine the prevalence and potential clinical value of detected molecular abnormalities and altered patterns of expression of mdm2 and p53 genes in adult soft tissue sarcomas.
|
8306343 |
1994 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Four affected members of the family with sarcoma or premenopausal breast cancer showed increased expression of p53 protein in their normal tissues as detected by immunohistochemistry.
|
7981072 |
1994 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Overexpression of p53 was seen in 27 of 46 sarcomas (59%), including 26 of 41 (63%) mixed mesodermal tumors, one of four (25%) leiomyosarcomas, and zero of one endometrial stromal sarcoma.
|
8272291 |
1994 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
We examined the potential clinical relevance of p53 overexpression in adults with soft-tissue sarcomas.
|
8133539 |
1994 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Our knowledge of the molecular biology of sarcomas has progressed considerably over the past year, with major emphasis on the role of p53 and MDM2 gene mutations.
|
7803538 |
1994 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
However, there is little information about the clinicopathologic significance of alterations of the p53 gene in soft tissue sarcomas (STS).
|
8174045 |
1994 |